ジェネリック注射剤の世界市場レポート 2025年

ジェネリック注射剤市場規模は、今後数年で急成長が見込まれます。2028年の年間平均成長率（CAGR）は13.6％で、2,094億7,000万米ドルに成長します。予測期間の成長は、高齢化人口の拡大、業界企業間の戦略的提携、規制の変化、ヘルスケアに対する意識の高まり、市場イノベーションの急増など、さまざまな要因によって予想されます。

がんと心血管疾患の増加が予想され、ジェネリック注射剤市場の成長を牽引します。制御不能な細胞増殖を特徴とするがんや、心臓や血管に影響を及ぼす心血管系疾患は、健康への懸念が蔓延しています。ジェネリック注射剤は、先発医薬品と同等の医薬品を提供することで、これらの疾患の治療に重要な役割を果たしています。2022年には、非感染性疾患（NCDs）に起因する世界の死亡者数4,100万人のうち、約74％が心血管疾患（死亡者数1,790万人）とがん（死亡者数930万人）によるものでした。このような注射剤が入手可能になることで、治療へのアクセスや購入しやすさが向上し、市場の成長に寄与しています。

高齢者人口の拡大は、ジェネリック注射剤市場の成長を促進すると予想されます。平均寿命の延びや出生率の低下により人口が高齢化するにつれ、ジェネリック注射剤の需要が高まる。これらの医薬品は、糖尿病、心血管疾患、骨粗しょう症など、高齢者の間で流行している健康状態の管理に一般的に使用されています。例えば、2041年までにオーストラリアの65歳以上の人口は、2021年の推定431万人から54％増の666万人になると予測されています。このような人口動態の変化により、高齢化社会のヘルスケアニーズに対応するジェネリック注射剤の需要が高まっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ジェネリック注射剤PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のジェネリック注射剤市場：成長率分析
• 世界のジェネリック注射剤市場の実績：規模と成長, 2019-2024
• 世界のジェネリック注射剤市場の予測：規模と成長, 2024-2029, 2034F
• 世界ジェネリック注射剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のジェネリック注射剤市場：製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体
• サイトカイン
• インスリン
• ワクチン
• その他の製品
• 世界のジェネリック注射剤市場コンテナタイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• バイアル
• アンプル
• プレミックス
• プレフィルドシリンジ
• その他のコンテナ
• 世界のジェネリック注射剤市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 静脈内
• 筋肉内
• 皮下
• その他の投与経路
• 世界のジェネリック注射剤市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• ドラッグストア
• オンライン処方箋販売店
• 世界のジェネリック注射剤市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍学
• 糖尿病
• 感染症
• 血液疾患
• 筋骨格障害
• ホルモン障害
• 疼痛管理
• 中枢神経疾患
• 心血管疾患
• 世界のジェネリック注射剤市場、モノクローナル抗体の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• IgGモノクローナル抗体
• IgMモノクローナル抗体
• その他のタイプのモノクローナル抗体
• 世界のジェネリック注射剤市場サイトカインの種類によるサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• インターフェロン
• インターロイキン
• 腫瘍壊死因子（TNF）阻害剤
• 世界のジェネリック注射剤市場インスリンの種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 速効型インスリン
• 持続性インスリン
• 複合インスリン
• 世界のジェネリック注射剤市場、ワクチンの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 不活化ワクチン
• 生弱毒化ワクチン
• 組み換えワクチン
• 世界のジェネリック注射剤市場、その他の製品のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ホルモン
• ペプチド
• 酵素

第7章 地域別・国別分析

• 世界のジェネリック注射剤市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のジェネリック注射剤市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ジェネリック注射剤市場：競合情勢
• ジェネリック注射剤市場：企業プロファイル
  • Baxter International Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc. Overview, Products and Services, Strategy and Financial Analysis
  • Fresenius Medical Care AG & Co. KGaA Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Merck & Co. Inc.
• Biocon Limited
• Lupin Limited
• Dr. Reddy's Laboratories Ltd.
• Teva Pharmaceutical Industries Ltd.
• Cipla Limited
• Aurobindo Pharma Limited
• Samsung Biologics Co. Ltd.
• Piramal Pharma Limited
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Hikma Pharmaceuticals PLC
• Par Pharmaceutical
• Pharmascience Inc.
• SAGENT Pharmaceuticals

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ジェネリック注射剤市場2029：新たな機会を提供する国
• ジェネリック注射剤市場2029：新たな機会を提供するセグメント
• ジェネリック注射剤市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Generic injectables, also known as sterile injectables, are medications identical in dosage, strength, performance, intended use, potential side effects, and method of administration to branded injectables. These drugs demonstrate bioequivalence, ensuring they function in the same way as their brand-name counterparts, delivering equivalent therapeutic benefits.

Within the realm of generic injectables, diverse categories exist, including monoclonal antibodies, cytokines, insulin, vaccines, and more. Monoclonal antibodies, for instance, are artificial proteins mirroring natural antibodies in the human body. They find application in treating various conditions such as breast cancer, leukemia, asthma, macular degeneration, arthritis, Crohn's disease, and transplant-related issues.

These injectables are packaged in various containers such as vials, ampoules, premix solutions, and prefilled syringes. Their administration involves different routes such as intravenous, intramuscular, subcutaneous, and others. These medications are distributed through channels including hospital pharmacies, retail pharmacies, drug stores, and online prescription outlets. They serve diverse medical conditions spanning oncology, diabetes, infectious diseases, blood disorders, musculoskeletal disorders, hormonal disorders, pain management, central nervous system (CNS) ailments, and cardiovascular diseases.

The generic injectables market size has grown rapidly in recent years. It will grow from$124.61 billion in 2024 to $143.13 billion in 2025 at a compound annual growth rate (CAGR) of 14.9%. The growth in the historic period can be attributed to cost-effectiveness, patent expirations, healthcare access initiatives, market competition, and global pharmaceutical trends

The generic injectables market size is expected to see rapid growth in the next few years. It will grow to $238.43 billion in 2029 at a compound annual growth rate (CAGR) of 13.6%. The growth in the forecast period can be attributed to the increasing aging population, strategic alliances, regulatory changes, rising healthcare awareness, and market innovation. Major trends in the forecast period include a focus on quality and regulatory compliance, adoption of the 505 (b) (2) regulatory pathway, development of novel drug delivery technologies, collaborations and partnerships in the industry, and increased focus on specialty injectable therapies.

The generic injectables market size is expected to see rapid growth in the next few years. It will grow to $209.47 billion in 2028 at a compound annual growth rate (CAGR) of 13.6%. Anticipated growth in the forecast period is expected due to various factors, notably the expanding aging population, strategic alliances between industry players, regulatory shifts, heightened awareness about healthcare, and a surge in market innovation.

The anticipated increase in cancer and cardiovascular diseases is set to drive the growth of the generic injectable market. Cancer, characterized by uncontrolled cell growth, and cardiovascular diseases affecting the heart and blood vessels are prevalent health concerns. Generic injectables play a vital role in treating these conditions by offering pharmaceutical equivalence to brand-name drugs. In 2022, approximately 74% of the 41 million global deaths attributed to noncommunicable diseases (NCDs) were due to cardiovascular diseases (17.9 million deaths) and cancer (9.3 million deaths). The availability of these injectables enhances treatment accessibility and affordability, contributing to the market's growth.

The expanding population of elderly individuals is expected to fuel the growth of the generic injectables market. As populations age due to increased life expectancy and declining fertility rates, the demand for generic injectables rises. These pharmaceuticals are commonly used in managing health conditions prevalent among older individuals, such as diabetes, cardiovascular diseases, and osteoporosis. For instance, projections indicate that by 2041, Australia's population aged 65 and above will grow by 54% to 6.66 million from an estimated 4.31 million in 2021. This demographic shift drives the demand for generic injectables catering to the healthcare needs of aging populations.

Product innovation emerges as a prominent trend shaping the generic injectables market. Key players in this market focus on advancing generic injectables to maintain competitiveness. In April 2022, Dr. Reddy's Laboratories, an Indian pharmaceutical company, introduced Treprostinil Injection in the U.S. market. This injection, approved by the U.S. Food and Drug Administration (USFDA), serves as a therapeutic equivalent generic version of Remodulin (treprostinil) Injection. It facilitates a smooth transition for patients requiring a shift from epoprostenol, aiding in the reduction of clinical deterioration.

Major companies in the generic injectables market are forging strategic partnerships and collaborations to fortify their market position. These partnerships, aimed at achieving specific business objectives, play a pivotal role in sustaining market presence. For example, in December 2023, ITAAN Pharma, a Canadian pharmaceutical company specializing in injectable medications, collaborated with ACIC Pharmaceuticals, also based in Canada. This strategic alliance aims to jointly develop generic injectables targeting the North American market, leveraging the strengths of both entities for mutual growth and success.

In April 2022, Hikma Pharmaceuticals PLC, a US-based biopharmaceutical firm, completed the acquisition of Custopharm Inc for $425 million. This strategic move by Hikma is geared towards broadening its portfolio of injectable medications while bolstering its research and development capabilities. Custopharm, also based in the US, specializes in generic pharmaceutical products, notably in the realm of generic injectables, aligning well with Hikma's objectives for portfolio expansion and R&D advancement.

Major companies operating in the generic injectables market include Baxter International Inc., Sanofi SA, AstraZeneca plc., Fresenius Medical Care AG & Co. KGaA, Johnson & Johnson, Merck & Co. Inc., Biocon Limited, Lupin Limited, Dr. Reddy's Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Cipla Limited, Aurobindo Pharma Limited, Samsung Biologics Co. Ltd., Piramal Pharma Limited, Bristol-Myers Squibb Company, Pfizer Inc., Hikma Pharmaceuticals PLC, Par Pharmaceutical, Pharmascience Inc., SAGENT Pharmaceuticals, AmerisourceBergen Corporation, Hospira Inc., Sandoz International GmbH, Singota Solutions Inc., MVASI Bevacizumab-awwb Syringes, Mylan N.V., Sun Pharmaceutical Industries Ltd., Endo International plc, Akorn Pharmaceuticals Inc., Wockhardt Limited

North America was the largest region in the generic injectable market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the generic injectables market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the generic injectables market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The generic injectables market consists of sales of drug solutions, dry solid injectables, drug solids suspended in a liquid medium, drug suspension for injection, drug emulsions, and biological injectables. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Generic Injectables Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on generic injectables market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for generic injectables ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The generic injectables market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Monoclonal Antibodies; Cytokines; Insulin; Vaccines; Other Products
• 2) By Container Type: Vials; Ampoules; Premix; Prefilled Syringes; Other Containers
• 3) By Route Of Administration: Intravenous; Intramuscular; Subcutaneous; Other Routes Of Administration
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Drug Stores; Online Prescription Stores
• 5) By Application: Oncology; Diabetes ; Infectious Diseases ; Blood Disorders ; Musculoskeletal Disorders ; Hormonal Disorders ; Pain Management ; CNS Diseases ; Cardiovascular Diseases
• Subsegments:
• 1) By Monoclonal Antibodies: IgG Monoclonal Antibodies; IgM Monoclonal Antibodies; Other Types Of Monoclonal Antibodies
• 2) By Cytokines: Interferons; Interleukins; Tumor Necrosis Factor (TNF) Inhibitors
• 3) By Insulin: Rapid-Acting Insulin; Long-Acting Insulin; Combination Insulin
• 4) By Vaccines: Inactivated Vaccines; Live Attenuated Vaccines; Recombinant Vaccines
• 5) By Other Products: Hormones; Peptides; Enzymes
• Companies Mentioned: Baxter International Inc.; Sanofi SA; AstraZeneca plc.; Fresenius Medical Care AG & Co. KGaA; Johnson & Johnson
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Generic Injectables Market Characteristics

3. Generic Injectables Market Trends And Strategies

4. Generic Injectables Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Generic Injectables Growth Analysis And Strategic Analysis Framework

• 5.1. Global Generic Injectables PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Generic Injectables Market Growth Rate Analysis
• 5.4. Global Generic Injectables Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Generic Injectables Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Generic Injectables Total Addressable Market (TAM)

6. Generic Injectables Market Segmentation

• 6.1. Global Generic Injectables Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Cytokines
• Insulin
• Vaccines
• Other Products
• 6.2. Global Generic Injectables Market, Segmentation By Container Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vials
• Ampoules
• Premix
• Prefilled Syringes
• Other Containers
• 6.3. Global Generic Injectables Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous
• Intramuscular
• Subcutaneous
• Other Routes Of Administration
• 6.4. Global Generic Injectables Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Drug Stores
• Online Prescription Stores
• 6.5. Global Generic Injectables Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Diabetes
• Infectious Diseases
• Blood Disorders
• Musculoskeletal Disorders
• Hormonal Disorders
• Pain Management
• CNS Diseases
• Cardiovascular Diseases
• 6.6. Global Generic Injectables Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• IgG Monoclonal Antibodies
• IgM Monoclonal Antibodies
• Other Types Of Monoclonal Antibodies
• 6.7. Global Generic Injectables Market, Sub-Segmentation Of Cytokines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Interferons
• Interleukins
• Tumor Necrosis Factor (TNF) Inhibitors
• 6.8. Global Generic Injectables Market, Sub-Segmentation Of Insulin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rapid-Acting Insulin
• Long-Acting Insulin
• Combination Insulin
• 6.9. Global Generic Injectables Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inactivated Vaccines
• Live Attenuated Vaccines
• Recombinant Vaccines
• 6.10. Global Generic Injectables Market, Sub-Segmentation Of Other Products, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hormones
• Peptides
• Enzymes

7. Generic Injectables Market Regional And Country Analysis

• 7.1. Global Generic Injectables Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Generic Injectables Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Generic Injectables Market

• 8.1. Asia-Pacific Generic Injectables Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Generic Injectables Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Generic Injectables Market, Segmentation By Container Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Generic Injectables Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Generic Injectables Market

• 9.1. China Generic Injectables Market Overview
• 9.2. China Generic Injectables Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Generic Injectables Market, Segmentation By Container Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Generic Injectables Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Generic Injectables Market

• 10.1. India Generic Injectables Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Generic Injectables Market, Segmentation By Container Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Generic Injectables Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Generic Injectables Market

• 11.1. Japan Generic Injectables Market Overview
• 11.2. Japan Generic Injectables Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Generic Injectables Market, Segmentation By Container Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Generic Injectables Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Generic Injectables Market

• 12.1. Australia Generic Injectables Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Generic Injectables Market, Segmentation By Container Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Generic Injectables Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Generic Injectables Market

• 13.1. Indonesia Generic Injectables Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Generic Injectables Market, Segmentation By Container Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Generic Injectables Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Generic Injectables Market

• 14.1. South Korea Generic Injectables Market Overview
• 14.2. South Korea Generic Injectables Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Generic Injectables Market, Segmentation By Container Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Generic Injectables Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Generic Injectables Market

• 15.1. Western Europe Generic Injectables Market Overview
• 15.2. Western Europe Generic Injectables Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Generic Injectables Market, Segmentation By Container Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Generic Injectables Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Generic Injectables Market

• 16.1. UK Generic Injectables Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Generic Injectables Market, Segmentation By Container Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Generic Injectables Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Generic Injectables Market

• 17.1. Germany Generic Injectables Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Generic Injectables Market, Segmentation By Container Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Generic Injectables Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Generic Injectables Market

• 18.1. France Generic Injectables Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Generic Injectables Market, Segmentation By Container Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Generic Injectables Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Generic Injectables Market

• 19.1. Italy Generic Injectables Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Generic Injectables Market, Segmentation By Container Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Generic Injectables Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Generic Injectables Market

• 20.1. Spain Generic Injectables Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Generic Injectables Market, Segmentation By Container Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Generic Injectables Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Generic Injectables Market

• 21.1. Eastern Europe Generic Injectables Market Overview
• 21.2. Eastern Europe Generic Injectables Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Generic Injectables Market, Segmentation By Container Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Generic Injectables Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Generic Injectables Market

• 22.1. Russia Generic Injectables Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Generic Injectables Market, Segmentation By Container Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Generic Injectables Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Generic Injectables Market

• 23.1. North America Generic Injectables Market Overview
• 23.2. North America Generic Injectables Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Generic Injectables Market, Segmentation By Container Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Generic Injectables Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Generic Injectables Market

• 24.1. USA Generic Injectables Market Overview
• 24.2. USA Generic Injectables Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Generic Injectables Market, Segmentation By Container Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Generic Injectables Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Generic Injectables Market

• 25.1. Canada Generic Injectables Market Overview
• 25.2. Canada Generic Injectables Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Generic Injectables Market, Segmentation By Container Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Generic Injectables Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Generic Injectables Market

• 26.1. South America Generic Injectables Market Overview
• 26.2. South America Generic Injectables Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Generic Injectables Market, Segmentation By Container Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Generic Injectables Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Generic Injectables Market

• 27.1. Brazil Generic Injectables Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Generic Injectables Market, Segmentation By Container Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Generic Injectables Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Generic Injectables Market

• 28.1. Middle East Generic Injectables Market Overview
• 28.2. Middle East Generic Injectables Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Generic Injectables Market, Segmentation By Container Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Generic Injectables Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Generic Injectables Market

• 29.1. Africa Generic Injectables Market Overview
• 29.2. Africa Generic Injectables Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Generic Injectables Market, Segmentation By Container Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Generic Injectables Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Generic Injectables Market Competitive Landscape And Company Profiles

• 30.1. Generic Injectables Market Competitive Landscape
• 30.2. Generic Injectables Market Company Profiles
  • 30.2.1. Baxter International Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AstraZeneca plc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Fresenius Medical Care AG & Co. KGaA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis

31. Generic Injectables Market Other Major And Innovative Companies

• 31.1. Merck & Co. Inc.
• 31.2. Biocon Limited
• 31.3. Lupin Limited
• 31.4. Dr. Reddy's Laboratories Ltd.
• 31.5. Teva Pharmaceutical Industries Ltd.
• 31.6. Cipla Limited
• 31.7. Aurobindo Pharma Limited
• 31.8. Samsung Biologics Co. Ltd.
• 31.9. Piramal Pharma Limited
• 31.10. Bristol-Myers Squibb Company
• 31.11. Pfizer Inc.
• 31.12. Hikma Pharmaceuticals PLC
• 31.13. Par Pharmaceutical
• 31.14. Pharmascience Inc.
• 31.15. SAGENT Pharmaceuticals

32. Global Generic Injectables Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Generic Injectables Market

34. Recent Developments In The Generic Injectables Market

35. Generic Injectables Market High Potential Countries, Segments and Strategies

• 35.1 Generic Injectables Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Generic Injectables Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Generic Injectables Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer